Amylin Analogue Pramlintide Triggers Migraine Attacks, Revealing a New Migraine Pathway
Pramlintide (an amylin analogue) induced migraine-like attacks in 41% of patients — similar to CGRP — suggesting amylin receptors contribute to migraine and that dual CGRP/amylin receptor antagonism could be more effective than CGRP-targeting alone.
Quick Facts
What This Study Found
Pramlintide induced headache in 88% and migraine-like attacks in 41% of patients (vs CGRP: 97% and 56%, differences not significant). The effects were mediated through amylin receptors, not the canonical CGRP receptor. Animal models confirmed amylin causes cutaneous hypersensitivity and light aversion.
Key Numbers
36 patients; headache 88% vs 97%; migraine 41% vs 56% (p=0.180); amylin receptor mediated; mouse: cutaneous hypersensitivity and light aversion with both amylin and CGRP
How They Did This
Randomized, double-blind, 2-way crossover clinical trial in 36 migraine without aura patients. Pramlintide or human αCGRP infusion on separate days. Supplemented with in vitro receptor pharmacology, mouse behavioral models, and tissue studies in rat, mouse, and human samples.
Why This Research Matters
Current anti-CGRP migraine drugs help many but not all patients. Identifying amylin receptor agonism as a novel migraine contributor suggests that blocking both amylin and CGRP receptors could help patients who don't respond to CGRP-targeting drugs alone.
The Bigger Picture
This study opens a new frontier in migraine treatment. Amylin and CGRP share receptor components but work through different receptors. Drugs that block both (like some next-generation therapies) could provide broader migraine relief than current CGRP-only approaches.
What This Study Doesn't Tell Us
Moderate sample size (36 patients). Migraine provocation models may not perfectly replicate spontaneous migraine. Pramlintide is designed for diabetes, not migraine — optimal amylin receptor manipulation for migraine needs development.
Questions This Raises
- ?Would dual amylin + CGRP receptor antagonists provide better migraine relief than CGRP antagonists alone?
- ?Does the amylin receptor contribute to CGRP-drug resistance in some patients?
- ?Could amylin receptor antagonists be developed as standalone migraine treatments?
Trust & Context
- Key Stat:
- 41% migraine from amylin Pramlintide triggered migraine-like attacks at rates approaching CGRP, but through different receptors — suggesting current anti-CGRP drugs miss an important migraine pathway
- Evidence Grade:
- High evidence: randomized, double-blind, crossover clinical trial with translational validation in cellular and animal models. Published in Annals of Neurology.
- Study Age:
- Published 2021. Dual CGRP/amylin receptor targeting for migraine is being explored in drug development.
- Original Title:
- Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.
- Published In:
- Annals of neurology, 89(6), 1157-1171 (2021)
- Authors:
- Ghanizada, Hashmat, Al-Karagholi, Mohammad Al-Mahdi(3), Walker, Christopher S(3), Arngrim, Nanna, Rees, Tayla, Petersen, Jakeb, Siow, Andrew, Mørch-Rasmussen, Mette, Tan, Sheryl, O'Carroll, Simon J, Harris, Paul, Skovgaard, Lene Theil, Jørgensen, Niklas Rye, Brimble, Margaret, Waite, Jayme S, Rea, Brandon J, Sowers, Levi P, Russo, Andrew F, Hay, Debbie L, Ashina, Messoud
- Database ID:
- RPEP-05401
Evidence Hierarchy
Frequently Asked Questions
Could amylin drugs cause migraines as a side effect?
This study shows pramlintide (an amylin analogue used for diabetes) can trigger migraine-like attacks when infused. For patients with migraine who use pramlintide for diabetes, this is worth discussing with their doctor, though regular doses may differ from the study's provocation model.
Why don't anti-CGRP drugs work for all migraine patients?
This study suggests one reason: amylin receptors also contribute to migraine through a separate pathway. Patients whose migraines are driven more by amylin than CGRP signaling might not respond to CGRP-targeting drugs. Blocking both pathways could help these patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05401APA
Ghanizada, Hashmat; Al-Karagholi, Mohammad Al-Mahdi; Walker, Christopher S; Arngrim, Nanna; Rees, Tayla; Petersen, Jakeb; Siow, Andrew; Mørch-Rasmussen, Mette; Tan, Sheryl; O'Carroll, Simon J; Harris, Paul; Skovgaard, Lene Theil; Jørgensen, Niklas Rye; Brimble, Margaret; Waite, Jayme S; Rea, Brandon J; Sowers, Levi P; Russo, Andrew F; Hay, Debbie L; Ashina, Messoud. (2021). Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.. Annals of neurology, 89(6), 1157-1171. https://doi.org/10.1002/ana.26072
MLA
Ghanizada, Hashmat, et al. "Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.." Annals of neurology, 2021. https://doi.org/10.1002/ana.26072
RethinkPeptides
RethinkPeptides Research Database. "Amylin Analog Pramlintide Induces Migraine-like Attacks in P..." RPEP-05401. Retrieved from https://rethinkpeptides.com/research/ghanizada-2021-amylin-analog-pramlintide-induces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.